Invex Therapeutics Ltd
ASX:IXC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Invex Therapeutics Ltd
ASX:IXC
|
AU |
Intrinsic Value
The intrinsic value of Invex Therapeutics Ltd (IXC) under the Base Case is 0.018 AUD per share.
Compared with the current market price of 0.115 AUD, the stock appears
Overvalued by 85% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Invex Therapeutics Does
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP).
- Headquarters
- Australia AU
- IPO date
- Jul 5, 2019
Earnings Waterfall
Invex Therapeutics Ltd
The intrinsic value for Invex Therapeutics Ltd (IXC) under the Base Case is 0.018 AUD.
Compared with the current market price of 0.115 AUD, the stock appears Overvalued by 85% .